Michael Gerald Meade

Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA.

Part of Tripos, Inc., Receptor Research Ltd. provides drug discovery informatics products and services. The company is based in Bude, UK. Receptor Research was acquired by Tripos, Inc. on November 18, 1997.

Simbec Research Ltd. provides clinical research service to pharmaceutical and biotechnology industries. It conducts drug trails for allergy, anti-infectives, cardiovascular, gastrointestinal, anti-inflammatory, oncology and respiratory. The firm also offers consultancy services, preparation of marketing authorization applications, and clinical trial applications. The company was founded in 1976 and is headquartered in Merthyr Tydfil, the United Kingdom.

The Royal Society of Chemistry is an organization that supports the chemical sciences community in making the world a better place. The Royal Society of Chemistry is based in London, UK, and has subsidiaries in the United Kingdom. The British company offers various opportunities in education, inclusion, and chemistry's ability to tackle challenges. The organization aims to advance excellence, connect chemical scientists, and shape the future of the chemical sciences for the benefit of humanity. The private company has a publishing portfolio that contains over one million articles, chapters, and records from across the chemical sciences and related fields. The company also provides solutions to help businesses engage with their audience of chemical scientists.

Morvus Technology Ltd. discovers, develops and commercializes of novel drugs and technologies in the oncology field. Its products include clinical candidates, research portfolio and non-core programmes. The company was founded by Philip John Burke and Roger Geoffrey Melton in April 2004 and is headquartered in Carmarthen, the United Kingdom.

Pharm-Olam International started operations in 1994 with the premise of delivering cost effective, quick-to-market clinical services in the emerging markets of Central and Eastern Europe. Since then, POI has expanded its services to more than 40 countries, including: North America, Western Europe, Central & Eastern Europe, Latin America, India, and South Africa. Today, POI has one of the largest global footprints of any CRO. They are committed to establishing and maintaining the industry's strongest multi-national presence. Its monitors have the most extensive knowledge of local and regional customs and sites across a broad range of therapeutic areas. POI has an entirely different model than other CROs- they call it global decentralization. The success of this model has been proven time and again.

Part of Shomer XV Ltd., Pharm-Olam International (UK) Ltd. is a clinical research organization that specializes in solving distinct challenges of small and mid-sized biopharma companies. The company is based in Bracknell, UK and operates under the name allucent. The British company offers contract research services and clinical expertise to ensure the success of their clients' products. The company's resource center provides the latest articles, blogs, brochures, and videos from their experts.

Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom.

Activiomics Ltd. develops innovative technologies that utilize mass spectrometry to interrogate and interpret the activity of cellular signaling pathways. It offers phosphoproteomics for biomaker discovery and drug profiling. The company was founded by Bart Vanhaesebroeck and Pedro Rodriguez Cutillas in 2009 and is headquartered in London, the United Kingdom.

Part of hVIVO PLC, hVIVO Services Ltd. is a British company that specializes in full-service viral challenge studies. The company is based in London, UK. The company's services include challenge models and lab services. The company was founded in 1988 by John Sidney Oxford.

IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland.

Imutex Ltd. is a British company that develops vaccines. The joint venture company is based in London, UK.

Keltic Pharma Therapeutics Ltd. is an Irish private company. The firm engages in drug discovery programs.

Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.